已收盤 05-08 16:00:00 美东时间
+0.850
+1.01%
UnitedHealthcare (UNH) is making its most aggressive push yet to simplify the prior authorization process, announcing Tuesday it will eliminate approval requirements for 30% of healthcare services tha...
05-05 22:09
EXCLUSIVE-Impactive aims to replace WEX CEO on board in proxy fight, sources say Impactive urges investors to elect 3 new directors Signals it is not aware of regulatory issues related to proxy fight Shareholders vote on directors May 5 By Svea Herbst-Bayliss NEW YORK, April 10 (Reuters) - Impactive
04-10 22:45
今日重点评级关注:Ascendiant Capital:维持RenovoRx"买入"评级,目标价从13美元升至13.5美元;Ascendiant Capital:维持Lucid Diagnostics"买入"评级,目标价从8.25美元升至9美元
04-10 18:27
Shares of HealthEquity (HQY) traded higher on Thursday after BMO Capital Markets boosted its longer-term growth estimates for the company and upgraded the stock to Outperform from Market Perform. Citi...
04-10 02:05
Top Wall Street analysts changed their outlook on top names. See analyst ratings page for upgrades, downgrades, and initiations. AA shares upgraded.
04-09 19:33
BMO Capital analyst Sean Dodge upgrades HealthEquity (NASDAQ:HQY) from Market Perform to Outperform and raises the price target from $85 to $105.
04-09 18:26
Healthequity ( ($HQY) ) has shared an announcement. On April 6, 2026, HealthEqu...
04-07 05:50
HealthEquity appoints Sanford Health CEO Bill Gassen to board HealthEquity elected Sanford Health CEO William “Bill” Gassen to board of directors, effective March 26, 2026. Board expanded to 10 directors, including eight independent directors. Gassen will join Audit and Risk Committee. He will also
03-30 20:34
HealthEquity, Inc. announced that William 'Bill' Gassen, CEO of Sanford Health, has been elected to its board of directors, effective March 26, 2026. Gassen will also serve on the Audit and Risk Committee and Talent, Compensation and Culture Committee. His appointment expands the Board to 10 directors, eight of whom are independent. Gassen brings extensive experience in healthcare delivery, financing, and addressing challenges in the healthcare s...
03-30 12:30
今日重点评级关注:RBC Capital:维持4D Molecular Therapeutics"跑赢大市"评级,目标价从32美元升至35美元;巴克莱:维持CytomX医疗"超配"评级,目标价从10美元升至16美元
03-20 15:53